Curis (NASDAQ:CRIS – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
A number of other analysts have also weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curis in a research note on Thursday, October 15th. HC Wainwright restated a “buy” rating on shares of Curis in a research note on Monday, August 17th. Finally, Zacks Research raised shares of Curis from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 9th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $43.00.
Get Our Latest Analysis on CRIS
Curis Stock Performance
Curis (NASDAQ:CRIS – Get Free Report) last released its earnings results on Thursday, November 12th. The biotechnology company reported ($1.94) earnings per share for the quarter, beating the consensus estimate of ($2.01) by $0.07. As a group, equities analysts anticipate that Curis will post -8.05 EPS for the current year.
Hedge Funds Weigh In On Curis
A number of large investors have recently added to or reduced their stakes in the stock. Focused Wealth Management Inc purchased a new position in Curis in the 2nd quarter valued at about $26,000. BlackRock Inc. purchased a new stake in Curis during the 2nd quarter worth approximately $28,000. Renaissance Technologies LLC raised its holdings in shares of Curis by 52.2% during the first quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock valued at $201,000 after acquiring an additional 125,823 shares during the last quarter. Flputnam Investment Management Co. acquired a new position in shares of Curis during the second quarter valued at approximately $128,000. Finally, Cable Car Capital LP purchased a new position in shares of Curis in the second quarter valued at approximately $696,000. 29.97% of the stock is currently owned by institutional investors and hedge funds.
About Curis
Curis, Inc. is a clinical-stage biotechnology company focused on developing treatments for cancer. Its research centers on targeted therapies designed to interfere with biological pathways involved in tumor growth and survival. The company’s clinical pipeline has included emavusertib, an oral small-molecule inhibitor of IRAK4 and FLT3 being investigated for certain blood cancers and other malignancies. Curis has also worked with partners to develop cancer drug candidates. Historically, Curis collaborated with Genentech on the development of Erivedge (vismodegib), a Hedgehog pathway inhibitor approved to treat certain cases of advanced basal cell carcinoma.
Read More
- Five stocks we like better than Curis
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
